Chile Mandates IEC 60601-1:2023 for Endoscopes from Oct 2026

Chile’s National Institute of Standardization (INN) announced on May 23, 2026, that all flexible video endoscopes, rigid endoscope systems, and associated light/camera systems entering the Chilean market must comply with IEC 60601-1:2023 and be registered with SERNAC as medical devices—effective October 1, 2026. This regulatory shift directly impacts manufacturers, exporters, and distributors of endoscopic equipment, especially those based in China, where a significant share of global endoscope supply originates.

Event Overview

On May 23, 2026, INN published an official notice stating that, effective October 1, 2026, importation of flexible video endoscopes, rigid endoscope systems, and their integrated light and imaging components into Chile will require certification to IEC 60601-1:2023. Concurrently, full registration with Chile’s consumer protection authority, SERNAC, is mandatory. No transitional period is provided; certificates issued under prior editions of IEC 60601-1 are no longer accepted for new imports after the deadline.

Industries Affected by Segment

Direct Exporters and Trading Companies

Exporters shipping endoscopic systems to Chile will face immediate compliance obligations. Because the requirement applies at the point of import, companies must secure updated certification before shipment—not after arrival. Non-compliant shipments risk rejection at customs or forced rework, delaying market access and increasing landed cost.

Manufacturers of Endoscopic Devices (OEM/ODM)

Manufacturers—particularly those supplying Chinese OEMs exporting to Chile—must redesign or revalidate product safety documentation to meet IEC 60601-1:2023’s updated risk management, usability, and essential performance requirements. Unlike earlier editions, the 2023 version introduces stricter clauses on cybersecurity awareness, alarm system reliability, and usability engineering—impacting firmware, labeling, and user manual content.

Supply Chain and Regulatory Support Providers

Third-party testing labs, certification bodies, and regulatory consultants supporting Chile-bound endoscope exports will see increased demand for IEC 60601-1:2023 assessments. However, capacity constraints may emerge, especially for labs accredited to perform the new usability validation and cybersecurity-related evaluations required under Clause 14.3 and Annex BB of the standard.

Key Actions for Affected Enterprises

Monitor Official Updates from INN and SERNAC

While the May 23, 2026 notice establishes the effective date and scope, technical implementation guidance—including acceptable test reports, recognized certification bodies, and SERNAC registration workflows—has not yet been published. Enterprises should track INN’s official bulletins and SERNAC’s medical device portal for procedural details expected in Q3 2026.

Prioritize Certification for High-Volume and High-Risk Product Lines

Given limited lab capacity and extended lead times for IEC 60601-1:2023 assessments (typically 4–6 months), exporters should identify top-selling or clinically critical models—e.g., gastrointestinal video endoscopes and laparoscopic rigid systems—and initiate certification well ahead of October 2026. Products with embedded software or network connectivity warrant early attention due to added cybersecurity evaluation steps.

Distinguish Between Regulatory Signal and Operational Readiness

The announcement signals a hard enforcement timeline, but actual customs enforcement depends on SERNAC’s ability to verify documentation upon entry. Enterprises should treat the October 1, 2026 date as a firm internal deadline—not a buffer—and align procurement, labeling, and packaging updates accordingly. Relying on informal grace periods or ad hoc approvals is not advisable.

Update Internal Compliance Roadmaps and Cross-Functional Coordination

Compliance requires coordination across R&D (for design verification), QA (for test report generation), regulatory affairs (for SERNAC submission), and logistics (for documentation handling). Companies should assign clear ownership, set milestone dates for each stage, and validate that existing quality management systems cover IEC 60601-1:2023’s expanded usability and risk management documentation requirements.

Editorial Perspective / Industry Observation

Observably, this mandate reflects Chile’s broader alignment with international medical device safety frameworks—particularly the IEC 60601 series’ evolution toward human factors integration and lifecycle-based risk control. Analysis shows it functions less as an isolated regulatory change and more as a signal of tightening convergence between Latin American markets and global standards. From an industry perspective, the absence of a transition period suggests Chile intends rapid, uniform enforcement—making proactive preparation more consequential than reactive adaptation. Current developments indicate this is already a binding outcome for future imports, not merely a policy proposal under review.

Chile’s enforcement of IEC 60601-1:2023 represents a concrete step toward harmonized medical device regulation in Latin America—but one that imposes measurable operational and financial pressure on exporters unprepared for its scope and timing. It is best understood not as a temporary hurdle, but as a structural recalibration of market access requirements for endoscopic technologies in Chile. Enterprises should treat it as a fixed compliance milestone requiring cross-departmental execution—not a negotiable or deferrable item.

Source: National Institute of Standardization of Chile (INN), official notice dated May 23, 2026.
Note: Technical implementation guidelines from SERNAC remain pending and are subject to ongoing monitoring.